Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Exact Sciences due to higher revenues, with a focus on how actual results will compare to estimates to influence stock price [1][2]. Company Summary - Exact Sciences is expected to report a quarterly loss of $0.37 per share, reflecting a year-over-year change of +26% [3]. - Revenues are projected to be $689.35 million, representing an 8.1% increase from the previous year [3]. - The consensus EPS estimate has been revised 4.76% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Prediction Insights - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Exact Sciences is higher than the Zacks Consensus Estimate, leading to an Earnings ESP of +61.75% [10][11]. - This positive Earnings ESP, combined with a Zacks Rank of 3, indicates a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Exact Sciences was expected to post a loss of $0.32 per share but actually reported a loss of $0.06, resulting in a surprise of +81.25% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Regeneron is expected to report earnings of $8.76 per share, indicating a year-over-year change of -8.3% [17]. - Regeneron's revenue is projected at $3.25 billion, up 3.3% from the previous year [17]. - The consensus EPS estimate for Regeneron has been revised 6.1% lower, resulting in an Earnings ESP of -0.94% and a Zacks Rank of 4, making it challenging to predict an earnings beat [18].